Biotech Maxion Therapeutics scores £58m round to tackle inflammatory disease

Maxion Therapeutics Raises $72M in Series A Funding

Maxion Therapeutics, a UK-based biotech company, raised $72 million in Series A funding led by General Catalyst.  The funding will accelerate its clinical-stage development, focusing on its lead KnotBody program, MAX001, and advancing other programs. Maxion develops antibody-based drugs for ion channel- and GPCR-driven diseases.

Maxion Therapeutics Secures $72M Series A to Advance Antibody-Based Therapeutics

Maxion Therapeutics is a Cambridge, UK-based biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.  It uses proprietary KnotBody technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins with antibodies.

A biotechnology company developing antibody-based drugs for ion channel- and GPCR-driven diseases.

2 months ago

Maxion Therapeutics Secures $72M Series A to Advance Antibody-Based Therapeutics

Covered on